Analytical Data
-
Gene name
IRF6
- Application
-
Alternative Names
IRF6；Interferon regulatory factor 6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14896
-
Expression Region
1-467aa
-
AA Sequence
MALHPRRVRLKPWLVAQVDSGLYPGLIWLHRDSKRFQIPWKHATRHSPQQ EEENAIFKAWAVETGKYQEGVDDPDPAKWKAQLRCALNKSREFNLMYDGT KEVPMNPVKIYQVCDIPQPQGSIINPGSTGSAPWDEKDNDVDEEDEEDEL DQSQHHVPIQDTFPFLNINGSPMAPASVGNCSVGNCSPEAVWPKTEPLEM EVPQAPIQPFYSSPELWISSLPMTDLDIKFQYRGKEYGQTMTVSNPQGCR LFYGDLGPMPDQEELFGPVSLEQVKFPGPEHITNEKQKLFTSKLLDVMDR GLILEVSGHAIYAIRLCQCKVYWSGPCAPSLVAPNLIERQKKVKLFCLET FLSDLIAHQKGQIEKQPPFEIYLCFGEEWPDGKPLERKLILVQVIPVVAR MIYEMFSGDFTRSFDSGSVRLQISTPDIKDNIVAQLKQLYRILQTQESWQ PMQPTPSMQLPPALPPQ
-
Molecular Weight
77 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The IRF6 (Interferon Regulatory Factor 6) gene plays a critical role in the development of the skin and the orofacial region, making it essential for understanding congenital conditions such as cleft lip and palate. Mutations in the IRF6 gene have been associated with various syndromic and nonsyndromic forms of these craniofacial anomalies, highlighting its importance in embryonic development. Research on IRF6 recombinant protein has gained momentum as scientists aim to elucidate its functional mechanisms and interactions at the molecular level. The study of this protein is particularly crucial for developing potential therapeutic strategies for individuals affected by craniofacial deformities. By expressing and purifying IRF6 as a recombinant protein, researchers can investigate its pathways, protein-protein interactions, and regulatory mechanisms, ultimately leading to a better understanding of how IRF6 contributes to tissue differentiation and development. Additionally, insights gained from these studies could pave the way for innovative treatments, potentially improving outcomes for patients with IRF6-related conditions. As genetic analysis and protein research continue to advance, the exploration of IRF6's role within developmental biology remains a vibrant field with significant implications for both fundamental science and clinical applications.
